EPS · actual vs est
$5.90 / $6.00Miss -1.7%
Revenue · actual vs est
$2.41B / $1.44BBeat +67.2%
Summary
Generated 2026-05-07
Management highlights
- Focus on building pipeline through partnerships with academic institutions and strategic investments in novel biology like Forte and Tensegrity. - MG is currently the majority of revenues and profits, with PFS driving growth. - DGF study for impasse pruvat is an exploratory phase two study with data followed out to 52 weeks for go/no-go decision on phase three. - Partnership with UNP for oral FCRN is progressing well and seen as a way to expand the market. - Combination strategy in INI, with platform studies to test different combinations for substantial efficacy benefits without safety trade-offs.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $5.90 | $6.00 | -1.7% | $2.58 |
| Revenue | $2.41B | $1.44B | +67.2% | $1.35B |
Transcript
May 7, 2026Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.